Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bronchial asthma~* Requirements for inhaled corticosteroid~* Positive skin prick test to house dust mite~* Positive radioallergosorbent test (RAST) to house dust mite~* Positive provocation test result to house dust mite~Exclusion Criteria:~* Serious chronic diseases~* Other perennial allergies

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
- Acaroid (Type: EXPERIMENTAL): The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).